Independent Director's Work Report for 2025
Dear shareholders and shareholder representatives:
As an independent director of China Resources BoYa Bio-Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company"), I have strictly adhered to the "Company Law of the People's Republic of China," "Securities Law of the People's Republic of China," "Self-Regulatory Guidelines No. 2 for Listed Companies on the Shenzhen Stock Exchange - Normative Operations of GEM Listed Companies," "Management Measures for Independent Directors of Listed Companies," and other relevant laws and regulations, as well as the "Articles of Association" and "Independent Director Work System." I have consistently maintained an objective, independent, and fair stance, diligently fulfilling my duties, making prudent independent decisions, providing professional review opinions on significant matters, and effectively exercising the supervisory and supporting roles of independent directors and specialized committees to safeguard the legitimate rights and interests of the Company and all shareholders, especially minority shareholders, while promoting standardized and efficient corporate governance. Below is my report on the performance of my duties in 2025:
I. Basic Information of the Independent Director
(1) Basic Information
I, Zhao Li, was born in 1957, hold Chinese nationality, and have no permanent residence abroad. I obtained a master's degree from Peking Union Medical College and a doctorate from Tokyo Metropolitan University. I have served as a professor and deputy director of the Pharmaceutical Chemistry Department at Hebei Medical University, deputy director of the Tangshan Food and Drug Administration, a member of the 9th CPPCC of Hebei Province, and a visiting professor at North China University of Science and Technology. I am currently an independent director of Shuyou Shen (Beijing) Bio-Pharmaceutical Co., Ltd. and an independent director of this Company. I have served as an independent director of the Company since February 3, 2021, and by the end of 2025, I will have completed five years of independent director duties.
(2) Independence Self-Assessment
I have completed the independence self-assessment as required by the regulatory authorities and confirmed that there are no circumstances affecting my independence as an independent director, in compliance with the "Management Measures for Independent Directors of Listed Companies" and other relevant regulations. The Company's board of directors has evaluated my independence and found no issues that hinder independent and objective judgment, confirming that I continue to meet the independence requirements.
II. Annual Performance Overview of the Independent Director
(1) Attendance at Board and Shareholder Meetings
In 2025, I attended all 10 board meetings and 4 shareholder meetings, thoroughly reviewing materials before meetings, actively participating in discussions during meetings, and prudently exercising my voting rights, voting in favor of all proposals without any absences, opposition, or abstentions. The specific attendance is as follows:
| Director Name | Total Board Meetings | In-Person Attendance | Attendance by Communication | Proxy Attendance | Absences | Consecutive Absences | Shareholder Meeting Attendance |
|---|---|---|---|---|---|---|---|
| Zhao Li | 10 | 9 | 1 | 0 | 0 | No | 4 |
(2) Attendance at Specialized Committee and Independent Director Meetings
- Specialized Committee Performance As a member of the Audit Committee, I attended all 8 committee meetings, reviewing 30 proposals, including the annual financial report, internal control evaluation, audit firm selection, related party transaction review, fundraising management, and asset disposal, ensuring compliance with procedures, fairness in pricing, and completeness of information disclosure. As a member of the Strategy and ESG Committee, I attended all 6 committee meetings, reviewing the ESG report, annual financial report, business plan formulation, and the disposal of Boya Xinhao.